H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Protagonist Therapeutics (PTGX) to $54 from $50 and keeps a Buy rating ...

H.C. Wainwright initiated coverage of Agios Pharmaceuticals (AGIO) with a Buy rating and $58 price target The firm views the company’s lead ...

IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell ...

Investment analysts at HC Wainwright issued their Q4 2025 EPS estimates for Prothena in a research note issued to investors on Friday, February 21st. HC Wainwright analyst A. Fein expects that the ...

HC Wainwright reiterated their neutral rating on shares of Ardelyx (NASDAQ:ARDX – Free Report) in a research report sent to ...

H.C. Wainwright adjusted its price target for Largo Resources Ltd. (NASDAQ:LGO) to $3.70, down from the previous $4.20, while maintaining a "Buy" rating on the stock. The firm's decision follows Largo ...

H.C. Wainwright reiterated a Buy rating and a price target of $18.00 on Enanta Pharmaceuticals (NASDAQ:ENTA) shares, significantly above the current price of $4.90. The stock is trading near its ...

Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings H.C. Wainwright & Co., LLC, announced its #1 Ranking ...

will participate in the H.C. Wainwright 3 rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:30 am ET. (PRNewsfoto/CARISMA Therapeutics Inc.) An audio webcast of the event ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (LSE:0VRQ) with a Buy recommendation. There are 575 funds or institutions reporting positions ...

Thursday, H.C. Wainwright reaffirmed a Buy rating on Precision BioSciences Inc . (NASDAQ:DTIL) with a steady price target of $60.00, significantly above the current trading price of $5.65. The ...